This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
Lay Description
To investigate the efficacy, safety and tolerability of BI 409306 once daily compared to placebo given for 52 weeks to subjects with attenuated psychosis syndrome.
Category
- Aging and Geriatric
- Genetics
- IRB Number
- 20180639HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Between 16 Years and 30 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
David Glahn
david.glahn@childrens.harvard.edu
Floyd Jones
+1 (210) 450-3158
jonesfa@uthscsa.edu
Amy Saklad
(210) 567-8229
saklada@uthscsa.edu
Mary Woolsey
(210) 567-8049
woolseym@uthscsa.edu
Floyd Jones
+1 (210) 450-3158
jonesfa@uthscsa.edu
Amy Saklad
(210) 567-8229
saklada@uthscsa.edu
Mary Woolsey
(210) 567-8049
woolseym@uthscsa.edu
Principal Investigator
David Glahn
Principal Investigator
David Glahn